Table 3.

Number and percent of patients who reported the adverse events that occurred in ≥10% of all study patients, by adverse event and treatment group

Adverse eventPlacebo, n = 38, n (%)Botulinum toxin type B, n = 39, n (%)
CD = cervical dystonia.
Dry mouth1 (3)17 (44)
Dysphagia2 (5)11 (28)
Neck pain secondary to CD8 (21)8 (21)
Infection6 (16)8 (21)
Injection site pain3 (8)7 (18)
Nausea3 (8)6 (15)